Regeneron Pharmaceuticals, Inc. (REGN)
Regeneron is a science-led company that discovers and develops medicines to treat serious diseases, from eye conditions to inflammatory illnesses.
Is Regeneron Pharmaceuticals, Inc. a good stock for a UK beginner?
The honest version: There's no rating here and nothing for sale. In its favour: Strong profit margins indicate an efficient business model. Worth weighing: Earnings growth has dipped recently, which can be a concern for investors.
Is this normal for this company?
Each figure against the range this same company has produced recently. Neither end of a range is the good end.
Share price divided by the earnings actually reported over the four most recent quarters. The range is the same calculation at each of this company's last few results, so roughly the past year.
Profit as a share of sales, from the company's own quarterly statements. The range covers the 5 quarters we hold, and the figure shown is its most recent one.
How these ranges are built
Every number here is the company's own reported figure, not a comparison with other companies. The ranges come from this company's own results and its share price. Where it reports in a different currency from the one its shares trade in, the price-to-earnings range is left out rather than mixing the two.
What does Regeneron Pharmaceuticals, Inc. do?
Regeneron focuses on finding new ways to treat complex health issues, often using its own unique technology to create targeted therapies. Its income comes from selling these specialised medicines to hospitals and pharmacies globally. Its future growth really comes down to how well their pipeline of new drugs performs in clinical trials.
On our factor screen it looks strongest on momentum and quality, and weakest on growth.
- ✓Pays a dividend - about 0.5% a year
- ✓Growing - revenue up about 17% over the year
- ✓Very profitable - turns about 28% of sales into profit
- ✓Low debt - a sturdier balance sheet
- Momentum screens high
- —
Does Regeneron Pharmaceuticals, Inc. pay a dividend?
Yes - Regeneron Pharmaceuticals, Inc. currently pays a dividend of about 0.5% a year, which is £4.70 a year for every £1,000 invested (the yearly payout as a share of the price). A dividend is a slice of profit handed to shareholders; the yield moves as the price moves, and a company can cut or stop it. An ISA doesn't shelter the US tax on this one →
What do the numbers say about Regeneron Pharmaceuticals, Inc.'s dividend?
There's no rating here, and we don't judge whether the dividend will continue - that would be advice. Here are the figures income investors usually look at, and what each one means, so you can weigh it up yourself.
Figures are from the latest available data and can be distorted by one-off results. Past payments don't predict future ones, and a dividend can be cut at any time. This lays out the numbers to help you understand them - it is not a view on what will happen.
Most recent ex-dividend date: 20 May 2026. To receive a dividend you must already own the shares before the ex-dividend date; become a holder on or after it and the previous owner keeps that payment. Why the price usually falls that morning →
Does Regeneron Pharmaceuticals, Inc. have more cash or more debt?
It holds about $7.99B in cash against about $2.71B of debt - so it has net cash of about $5.29B. More cash than debt is a cushion: it does not need to borrow just to cover what it owes.
From the latest reported balance sheet. Cash and debt levels change, and some borrowing is normal - this is context, not a judgment.
What do Regeneron Pharmaceuticals, Inc.'s numbers mean?
How has it performed?
Growth of £1,000, the worst fall, and year by year
Over about 2 years to 2026-09-11. This is the share price only - reinvesting the dividends would add to it. And it's the USD return - as a UK investor your actual £ return also moves with the exchange rate. Past performance is not a guide to the future, and it could just as easily have fallen.
How much has Regeneron Pharmaceuticals, Inc. actually fallen?
Over the last 2 years of daily prices, Regeneron Pharmaceuticals, Inc. fell as much as −60% from a high to a later low. Falls like this are normal when you own a share.
Past falls are not a forecast - it can fall further, or recover.
How has it done year by year?
Calendar-year total return - the share price with dividends reinvested - from adjusted closing prices. The current year is only part-complete. Past returns are not a guide to the future.
A closer look at the numbers
Ownership, earnings history, where the money goes, and the outlook range
Does the share price tell you if it's cheap or expensive?
Who owns Regeneron Pharmaceuticals, Inc.?
About 95% of Regeneron Pharmaceuticals, Inc., or about 95 in every 100 shares, is held by big institutions such as pension and index funds, and company insiders hold about 2%. The rest, roughly 3%, is held by the public and smaller investors.
What this does and doesn't tell you
This is a recent snapshot of the share register, and it moves. We don't read anything into who owns what - a high institutional share is common for any large listed company and is not a signal about it.
Based on beta - how much the price swings versus the whole market. Bumpier isn't bad; it just means a rougher ride, which matters more the sooner you might need the money.
Prices move on results, news and the mood of the whole market - no single headline explains a day, and a quiet week is usually just noise, not a signal.
How much money does Regeneron Pharmaceuticals, Inc. make?
Revenue and profit by quarter, and how much of each sale turns into profit.
Where does each £100 of Regeneron Pharmaceuticals, Inc.'s sales go?
A rough split of the latest full-year figures: of every £100 of sales, about £56 covers making the product or service, £16 goes on running costs, tax and interest, and about £28 is left as profit. Margins vary a lot by industry, and one-off items can distort a single year.
When does Regeneron Pharmaceuticals, Inc. report earnings, and how did recent quarters go?
Regeneron Pharmaceuticals, Inc. is next scheduled to report on about 2026-10-28 - dates can move, and we don't predict results; this just tells you when to look.
‘Beat’ and ‘missed’ are against what analysts expected, not whether the business is doing well.
| Reported | Expected EPS: The earnings per share analysts expected for the quarter - the average of their forecasts. 'Beating' or 'missing' is measured against this number. | Actual EPS | vs expected |
|---|---|---|---|
| 2026-07-30 | $10.21 | $14.29 | Beat +40% |
| 2026-04-29 | $8.90 | $9.47 | Beat +6% |
| 2026-01-30 | $10.75 | $11.44 | Beat +6% |
| 2025-10-28 | $9.64 | $11.83 | Beat +23% |
| 2025-08-01 | $8.44 | $12.89 | Beat +53% |
| 2025-04-29 | $8.48 | $8.22 | Missed -3% |
Across the last 6 quarters here, Regeneron Pharmaceuticals, Inc. came in ahead of what analysts expected 5 times. One quarter is noise, not a trend.
See who else reports over the next two weeks →
Where these figures come from
Each quarter a company reports its results against a consensus of analyst forecasts. The figures here are reported versus expected earnings per share from published results; the expectation is that analyst consensus, not our view. Report dates are estimates and can move.
What are the scenarios for Regeneron Pharmaceuticals, Inc.?
An illustrative range for the year ahead — not a prediction or a price target.
What are the pros, cons and common questions?
The case each way, and the questions people ask
Breakthrough discoveries lead to major new revenue streams.
Failure to innovate or loss of key patent exclusivity.
What are the pros and cons of Regeneron Pharmaceuticals, Inc.?
A balance check, not a score or verdict.
- Strong profit margins indicate an efficient business model.
- Low beta suggests the stock is less volatile than the broader market.
- Double-digit revenue growth: How fast the company's sales grew versus a year ago. shows healthy demand for their products.
- Earnings growth has dipped recently, which can be a concern for investors.
- The pharmaceutical industry is notoriously expensive and slow to develop new products.
- Small dividend yield: The yearly dividend as a percentage of the share price - roughly the income you'd earn from dividends alone. may not appeal to those looking for regular income.
- Heavy reliance on the success of a few key drugs.
- Strict government regulations can impact pricing and profitability.
- The high cost of research and development means money can be spent with no guarantee of a successful medicine.
The write-up's own warning lights — if these start happening, the case above changes.
- A major, unexpected failure in a late-stage clinical trial.
- Significant changes to government healthcare spending policies that limit drug prices.
Common questions about Regeneron Pharmaceuticals, Inc.
Does Regeneron Pharmaceuticals, Inc. pay a dividend?
Yes - Regeneron Pharmaceuticals, Inc. currently pays a dividend of about 0.5% a year. Dividends are a share of profit paid to holders; the yield moves with the price and payouts can be cut.
When does Regeneron Pharmaceuticals, Inc. report earnings next?
Regeneron Pharmaceuticals, Inc. is next scheduled to report results on about 2026-10-28. Report dates are estimates and can move; this is a diary note for when to look, not a forecast of the outcome.
More in Healthcare
Agilent Technologies, Inc.
Viatris Inc.
CVS Health Corporation
DaVita Inc.
Universal Health Services, Inc.
Quest Diagnostics Incorporated
Humana Inc.
ResMed Inc.Built from public filings & market prices, checked for an education-only tone, and never a price target. How we make these →
This plain-English summary was auto-generated on 2026-08-02 from public data and checked for an education-only, no-advice tone (the figures above carry their own, usually fresher, 'as of' date). It's information, never a recommendation.